Table 1.
Clinical and laboratory characteristic of 98 MPNs at diagnosis according to diagnosis.
| IMF | MPN-U | PV | TE | P value | |
|---|---|---|---|---|---|
| Number of patients | 9 | 8 | 26 | 55 | na |
| M/F | 8/1 | 3/5 | 17/9 | 25/30 | 0.04 |
| Median age, years (range) | 68 (54–82) | 69 (43–67) | 72 (30–85) | 63 (25–89) | 0.04 |
| Follow-up days, median (range) | 885.5 (397–2130) | 1314 (350–2707) | 1358.5 (128–5871) | 2137 (179–4708) | 0.1 |
| Hb, g/100 mL (range) | 15.1 (12.1–17.4) | 16.1 (12.5–19.1) | 18.0 (14.5–21.5) | 14.9 (11.1–18.1) | 0.0001 |
| WBC × 109/L (range) | 7.43 (5.52–13.82) | 7.73 (5.4–15.53) | 10.98 (1.7–19.6) | 8.3 (3.18–16.71) | 0.05 |
| Monocytes × 109/L (range) | 0.48 (0.08–0,89) | 0.4 (0.3–0.82) | 0.45 (0.02–1.55) | 0.45 (0.11–0.78) | 0.8 |
| Plt × 109/L (range) | 615 (429–1094) | 629 (181–1006) | 481 (134–1745) | 684 (443–1750) | 0.0001 |
| JAK2 V617F n (%) | 6/9 (66.6) | 6/8 (75) | 26/26 (100) | 35/55 (63.6) | 0.0001 |
| JAK2 V617F burden median % (range) | 40 (5–64) | 17 (4–40) | 60 (24–90) | 14 (5–59) | 0.0001 |
| EEC n (%) | 6/9 (66.6) | 6/8 (75) | 23/26 (88.5) | 41/55 (74.5) | 0.1 |
| CGU-MK n (%) | 3/9 (33.3) | 4/8 (37.5) | 16/26 (61.5) | 36/55 (65.5) | 0.1 |
| CD34 + SP × 109/L (range) | 0.051 (0.013–0.25) | 0.021 (0.0046–0.051) | 0.040 (0.0035–0.5) | 0.024 (0.0015–0.61) | 0.07 |
| CD34 + SP (%) (range) | 0.05 (0.035–0.45) | 0.03 (0.01–0.09) | 0.04 (0.01–0.56) | 0.03 (0.0015–0.27) | 0.07 |
| Bone marrow cellularity % (range) | 60 (30–90) | 40 (20–80) | 80 (60–95) | 50 (20–98) | 0.0001 |
| Single cytogenetic abnormality (n) | 1/9 | 2/8 | 2/26 | 0/54 | 0.3 |
| Complex karyotype (n) | 0/9 | 0/8 | 0/26 | 1/54 | |
| Trisomy (n) | 0/9 | 0/8 | 1/26 | 0/54 | |
| Palpable splenomegaly (n) | 6/9 | 3/8 | 16/26 | 15/55 | 0.7 |
| Splenic square cm2 (range) | 50 (26–102) | 43,5 (37–65) | 63 (25–200) | 40 (28–105) | 0.04 |
| Arterial thromboses (n) | 5/9 | 0/8 | 6/26 | 12/55 | 0.6 |
| Venous thromboses (n) | 1/9 | 0/8 | 6/26 | 3/55 | |
| Spontaneous haemorrhage (n) | 0/9 | 0/8 | 1/26 | 1/55 | 0.7 |
| Posttraumatic haemorrhage (n) | 1/9 | 0/9 | 0/26 | 1/55 | |
| Cytoreductive treatment (n) | 7/9 | 7/8 | 26/26 | 42/55 | 0.06 |